Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Germany
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Poteligeo (mogamulizumab-kpkc) is a monoclonal antibody approved by the FDA for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.
Poteligeo targets CCR4, a receptor found on the surface of malignant T cells in mycosis fungoides and Sézary syndrome (both forms of cutaneous T-cell lymphoma). By binding to CCR4, Poteligeo helps the immune system recognize and destroy these malignant cells.
Poteligeo is intended for adults with mycosis fungoides or Sézary syndrome whose disease has relapsed or is refractory after at least one prior line of systemic treatment.
The recommended dose of Poteligeo is 1 mg/kg administered intravenously over at least 60 minutes on Days 1, 8, 15, and 22 of the first 28-day cycle, then on Days 1 and 15 of each subsequent 28-day cycle.
Poteligeo does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.
Severe and fatal skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported. Skin reactions should be monitored closely throughout treatment.
Fatal and life-threatening infusion reactions have occurred, most commonly during or shortly after the first infusion. Patients should be monitored closely during infusions.
Fatal and life-threatening infections, including sepsis and pneumonia, have been reported. Patients should be monitored for signs of infection.
Fatal and serious complications, including graft-versus-host disease, have occurred in patients who undergo allogeneic hematopoietic stem cell transplantation after Poteligeo treatment.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Poteligeo is manufactured and marketed by Kyowa Kirin. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating hematologist-oncologist or dermatologist confirming diagnosis of mycosis fungoides or Sézary syndrome and prior treatment history. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for cutaneous T-cell lymphoma, Poteligeo is sourced through authorized channels and imported under GDP-compliant, cold-chain logistics to preserve product quality throughout transit.
NPP sources Poteligeo directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Poteligeo requires refrigerated storage at 2°C to 8°C, protected from light, and must not be frozen or shaken. NPP maintains a continuous, monitored cold chain throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile cold-chain logistics to the patient's city.
Patients across India can access Poteligeo through NPP's regulated import pathway, with hematology-oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support hematology-oncology care coordination and documentation for Poteligeo access.
Delhi's major hospitals assist patients with prescription support and documentation for Poteligeo.
Bangalore's specialist network offers access coordination for eligible cutaneous T-cell lymphoma patients seeking Poteligeo.
Chennai-based hematology specialists coordinate Poteligeo access alongside comprehensive lymphoma care.
Hyderabad's care institutions support patients pursuing Poteligeo therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Poteligeo.
Pune-based specialists assist with prescription support and Poteligeo treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Poteligeo.
Kochi's specialist units assist patients with the documentation needed for Poteligeo access.
Chandigarh's care centers support Poteligeo treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Poteligeo access process.
Lucknow-based centers assist patients pursuing Poteligeo therapy.
Bhubaneswar's institutions support access to Poteligeo for eligible patients.
Guwahati's specialists help coordinate Poteligeo access for patients across the Northeast.
Patients in other cities across India can also access Poteligeo through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: FDA
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
